COMP <GO>
AXGN vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
Axogen Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: AXGN 3
— LLY 11
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
LAST: $49.37 (-0.52%) • MKT CAP: $2.96B
roic
-2.60%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXGN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXGN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 83.64% | -9.34 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -2.60% | 32.36% | -34.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.10% | 2.30% | -2.40 | LLY | /fcf-yield <GO> |
| Operating Margin | -3.50% | 40.21% | -43.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 31.90% | -38.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 45.51% | -25.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.64 | 9.29 | +9.35 | AXGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 73.9 | 77.9 | -3.95 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.51 | +0.59 | AXGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 26.3x | -8.25 | AXGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.96B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXGN REV | LLY REV | AXGN GROSS % | LLY GROSS % | AXGN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $225.2M | $65.18B | 74.3% | 83.0% | -$2.9M | $16.81B |
| FY 2024 | $187.3M | $45.04B | 75.8% | 81.3% | $1.4M | $8.82B |
| FY 2023 | $159.0M | $34.12B | 44.0% | 79.3% | -$12.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXGN // BETA 1.10
LLY // BETA 0.51